TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Qiagen ( (QGEN) ) is now available.
QIAGEN N.V. has announced the pre-release of its half-year financial report for 2025, covering the period from January 1 to June 30. The report is scheduled to be published on September 30, 2025, and will be available on the company’s official website. This announcement is part of the company’s compliance with financial reporting regulations and is expected to provide stakeholders with insights into the company’s financial performance and strategic direction for the first half of the year.
The most recent analyst rating on (QGEN) stock is a Buy with a $52.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, specializing in sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its focus on providing solutions that enable customers to gain valuable insights from the building blocks of life, including DNA, RNA, and proteins.
Average Trading Volume: 1,444,660
Technical Sentiment Signal: Buy
Current Market Cap: $9.9B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.